Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
Marie José KerstenKarima AmaadorMonique C MinnemaJosephine M I VosKazem NasserinejadMarcel KapEfstathios KastritisMaria GavriatopoulouWillem KraanMartine E D ChamuleauDries DeerenLidwine W TickJeanette K DoorduijnFritz OffnerLara H BöhmerRoberto D LiuSteven T PalsMeletios- Athanasios DimopoulosPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Combination of IRD shows promising efficacy with manageable toxicity in patients with relapsed or refractory WM.